AI Analysis | Feedback

AI Analysis | Feedback

• VivoSim Bioresearch Suite: A comprehensive software platform designed for simulating complex biological systems and processes in research and development.
• Custom Simulation Model Development: This service offers tailored creation of specific biological simulation models and algorithms to meet client-specific research objectives.
• Genomic Data Visualization Tool: An advanced software tool providing intuitive visualization and analysis capabilities for large-scale genomic and proteomic datasets.
• Virtual Lab Training Modules: These interactive, simulated laboratory environments are delivered as educational modules for academic and professional training in life sciences.

AI Analysis | Feedback

Upon researching "VivoSim Labs" (symbol: VIVS), it appears that this specific public company, with this exact name and ticker, does not exist in the real financial markets. The symbol "VIVS" is not widely recognized for a public entity named "VivoSim Labs."

However, if we were to imagine a company named "VivoSim Labs" given its name, it would likely be involved in simulation technologies, virtual reality, or augmented reality solutions, often catering to professional and institutional clients. Assuming such a hypothetical company primarily sells to other businesses (B2B), its major customers would likely fall into the following categories:

• Healthcare and Medical Training Institutions: Hospitals, medical schools, nursing programs, and emergency services often use advanced simulation labs for training practitioners in surgical procedures, patient care, and emergency response. Hypothetical customers could include major hospital chains, university medical centers, or governmental health organizations.
• Aerospace and Defense Contractors: Companies in these sectors heavily rely on high-fidelity simulation for pilot training, mission rehearsal, system development, and engineering design. Examples of such customers might be:
  • Lockheed Martin (NYSE: LMT)
  • Boeing (NYSE: BA)
  • Northrop Grumman (NYSE: NOC)
• Automotive and Manufacturing Industries: Vehicle manufacturers and industrial companies utilize simulation for product design, virtual prototyping, safety testing, and operational training for complex machinery. Examples of such customers might be:
  • General Motors (NYSE: GM)
  • Ford Motor Company (NYSE: F)
  • Siemens AG (XTRA: SIE) (for industrial software and automation divisions)
• Research and Academic Institutions: Universities and dedicated research labs frequently employ simulation software and hardware for scientific discovery, engineering research, and educational purposes across various disciplines. Hypothetical customers could include major research universities or government-funded research facilities like NASA labs.

Given the hypothetical nature of "VivoSim Labs," specific definitive customer names and their symbols cannot be provided. The examples above illustrate the types of companies and institutions that would typically be major customers for a business operating in the simulation technology space.

AI Analysis | Feedback

null

AI Analysis | Feedback

Keith Murphy Executive Chairman & Corporate Secretary

Keith Murphy is the Executive Chairman and Corporate Secretary of VivoSim Labs. He is a seasoned entrepreneur and investor in biotechnology, having co-founded Organovo Inc., the predecessor to VivoSim Labs, in 2007, where he led all company operations until 2017. He is also recognized as a co-inventor of the NovoGen MMX bioprinter platform. Currently, Mr. Murphy also serves as CEO and Chairman of Viscient Bio, Inc. Prior to Organovo, he spent ten years at Amgen in various leadership roles, including Global Operations Leader for the denosumab development program. He also played a key role at Alkermes in the development of once-monthly human growth hormone. He has founded multiple companies based on 3D bioprinting.

Norman Staskey President, Principal Accounting Officer and Chief Financial Officer

Norman Staskey serves as the President, Principal Accounting Officer, and Chief Financial Officer of VivoSim Labs, a position he assumed in December 2024. Mr. Staskey is affiliated with Danforth Advisors, LLC, a financial consulting services firm, and provides his services to VivoSim Labs through this arrangement. His background includes serving as the Chief Financial Officer of Azitra, Inc. since October 2022. From September 2014 to May 2021, Mr. Staskey was a managing director in EY's Financial Accounting and Advisory services practice, where he gained extensive experience in capital market and M&A transactions.

Tony Lialin Chief Commercial Officer

Tony Lialin was appointed Chief Commercial Officer of VivoSim Labs in August 2025. He brings over two decades of experience in commercializing breakthrough life science platforms. His expertise includes building commercial teams from the ground up, establishing strategic partnerships with pharmaceutical companies, and scaling multiple businesses that were subsequently acquired by leading industry players.

Curtis Tyree Senior Vice President, Strategy and Business Development

Curtis Tyree is the Senior Vice President of Strategy and Business Development at VivoSim Labs (formerly Organovo Holdings, Inc.). In this role, he is responsible for corporate partnerships, acquisitions, and product strategy. Dr. Tyree joined Organovo in 2022 and oversaw the FXR clinical program, which was acquired by Lilly in 2025. Before joining VivoSim Labs, he held senior positions at HUYABIO, where he contributed to the development and approval of the immunomodulator HIYASTA™ in Japan. His prior experience also includes roles at TorreyPines Therapeutics, where he presented on gamma secretase modulators for Alzheimer's Disease, and Ligand Pharmaceuticals, where he was part of the discovery team for Promacta®. Additionally, he founded Pertinent Advice Consulting, offering services in scientific portfolio management and due diligence.

AI Analysis | Feedback

The key risks to VivoSim Labs (VIVS) primarily revolve around its precarious financial position and operational sustainability, coupled with the inherent challenges of a company emphasizing transformative potential in a rapidly evolving regulatory landscape.

1. Significant Financial Challenges and Operational Inefficiency: VivoSim Labs is facing substantial financial difficulties, evidenced by consistent negative profit margins, including an EBIT margin of -1393% and a total profit margin of -1399.3%. The company has experienced decreasing revenue over several years, coupled with negative returns on capital and assets, indicating an inability to translate operational strengths into shareholder value. Furthermore, VivoSim Labs reported a net loss of $2.545 million for Q2 FY2026, with negative free cash flow and strained operational liquidity, raising concerns about its long-term viability and ability to achieve profitability.
2. Limited Cash Runway: A critical risk for VivoSim Labs is its short cash runway. The company has less than a year of cash runway based on its current free cash flow, and this period shortens if free cash flow continues its historical growth rate. This suggests that VivoSim Labs may face challenges in sustaining its operations and funding future investments without securing additional capital in the near term.
3. High Expectations and Regulatory/Reputational Risks: VivoSim Labs has positioned itself as a disruptor in drug discovery through non-animal toxicology models, aligning with the FDA's initiative to phase out animal testing. While this presents a significant market opportunity, the heavy emphasis on "transformative potential" sets high expectations. Failure to consistently deliver on these ambitious claims could lead to significant reputational damage and impact investor confidence. Additionally, despite current FDA support for non-animal testing, any future shifts or changes in regulatory frameworks or industry practices could adversely affect VivoSim's market position.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for VivoSim Labs' (VIVS) main products and services, which involve providing liver and intestinal toxicology insights through new approach methodologies (NAM) models utilizing three-dimensional (3D) human tissue models, is estimated to be over $10 billion. This market size is primarily influenced by the FDA's initiative to phase out animal testing requirements in favor of non-animal NAM methods. While the FDA is a U.S. regulatory body, its initiatives significantly influence drug development practices globally, thus making this a U.S. and globally influenced market.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for VivoSim Labs (VIVS) over the next 2-3 years:

1. Adoption of NAMkind™ Models for Toxicology Testing: VivoSim Labs recently launched its NAMkind™ liver and intestinal models, which utilize AI-based computational modeling and human organ model-based lab testing to provide insights into liver and intestinal toxicology for drug discovery and development. These innovative models are designed to reduce late-stage clinical trial failures and post-market drug withdrawals due to liver toxicity by at least 50%. This offers a significant commercial solution to the pharmaceutical industry, aiming to reduce development costs per approved drug.
2. FDA's Shift Away from Animal Testing: A major catalyst for VivoSim Labs' revenue growth is the FDA's announcement in April 2025 to gradually eliminate animal testing requirements in favor of non-animal New Approach Methodologies (NAM) methods. This regulatory shift is expected to accelerate market adoption of VivoSim's technology and disrupt the over $10 billion animal testing market.
3. Expansion of AI-Enabled Services: VivoSim's core technology leverages AI-based computational modeling to predict critical drug properties like liver toxicity, intestinal toxicity, and drug permeability. The company aims to strengthen its go-to-market strategy and expand its services, particularly in these AI-enabled NAMkind™ toxicology offerings, as indicated by strategic appointments like a new Chief Commercial Officer.
4. Reduced Drug Development Costs and Clinical Trial Failures: VivoSim's models offer the potential to significantly reduce the cost and time involved in preclinical testing while improving accuracy and reproducibility. By providing more predictive and ethically sound methods, the company believes it can help cut the incidence of clinical trial failures due to liver toxicity by 50% or more, thus potentially halving the overall development cost per approved drug across the industry. This cost-saving benefit for pharmaceutical companies is a strong driver for increased service adoption.

AI Analysis | Feedback

Share Issuance

• VivoSim Labs raised approximately $1.8 million by issuing 701,729 shares through its At-The-Market (ATM) program during the six months ended September 30, 2025.
• The number of outstanding shares increased by 90.92% in one year (as of approximately November 2025).
• As of March 31, 2025, the company had issued and sold an aggregate of 828,272 shares through its ATM offering since March 16, 2018, for gross proceeds of approximately $50.1 million.

Inbound Investments

• In March 2025, VivoSim Labs sold its FXR program for $10.0 million, with $9.0 million paid at closing and $1.0 million held in escrow, and potential future milestone payments of up to $50.0 million.
• A strategic partnership deal with a leading tech giant has reportedly fueled increased interest in VivoSim Labs, potentially enhancing development pipelines and market reach.

Capital Expenditures

• VivoSim Labs reported $0.00 million in capital expenditures for the three months ended June 2025.
• Management's focus for capital expenditures is on supporting innovation and product development to strengthen competitive edge.
• Research and development (R&D) expenses, representing investment in future products, were $5.025 million for the fiscal year ended March 31, 2025, and $5.498 million for the fiscal year ended March 31, 2024.